Skip to main content
Fig. 7 | Proteome Science

Fig. 7

From: A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma

Fig. 7

The predictive value of the prognostic model for immunotherapy and chemotherapy in TCGA-LIHC dataset. A The proportion of false and true responders in low- and high-risk groups analyzed by TIDE. False and true indicate non-responsive and responsive to immune checkpoint blockade. ANOVA test was performed, and P values transferred as –log10 (P value) were shown in the upper box. B Comparison of TIDE score between the two risk groups. Student t test was performed. C Submap analysis for analyzing the similarity between non-treated samples and anti-PD-1 treated samples. Bonferroni corrected P values were indicated in the box. D-H Estimated IC50 values of cisplatin (D), imatinib (E), sorafenib (F), salubrinal (G) and pyrimethamine (H) in two risk groups. Student t test was performed. PD, progressive disease. SD, stable disease. PR, partial response. CR, complete response. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

Proteome Science

ISSN: 1477-5956